Who Paid My Doc
James Harding
Hematology & Oncology New York, NY Medical Doctor
NPI 1306003793 CMS profile 854935
1275 York Ave, Box 8, New York, NY 10065
General payments
$125,447
Research payments
$16,842
Ownership & investment interest
$0
Research they led as principal investigator
$5,917,975
Through program year 2025, James Harding of New York, NY is reported in the CMS Open Payments database as having received $125,447 across 105 general payments and $16,842 in research payments paid to them. Separately, studies naming them as principal investigator received $5,917,975 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $35,148 | 21 | |
| 2024 | General | $27,076 | 16 | |
| 2024 | Research | $4,790 | 2 | |
| 2023 | General | $34,449 | 36 | |
| 2022 | General | $12,677 | 15 | |
| 2022 | Research | $780 | 1 | |
| 2021 | General | $8,296 | 4 | |
| 2021 | Research | $4,760 | 3 | |
| 2020 | General | $1,644 | 3 | |
| 2019 | General | $6,157 | 10 | |
| 2019 | Research | $6,512 | 2 |
Beside peers
- James Harding
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to James Harding were reported at $35,148. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | James Harding | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $6,157 | $529 | $121–$2,516 | $163 |
| 2020 | $1,644 | $339 | $82–$2,213 | $114 |
| 2021 | $8,296 | $263 | $49–$1,965 | $132 |
| 2022 | $12,677 | $416 | $103–$2,395 | $149 |
| 2023 | $34,449 | $542 | $125–$2,646 | $160 |
| 2024 | $27,076 | $692 | $141–$3,008 | $164 |
| 2025 | $35,148 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
447
Drug cost
$2,079,472
Branded share of claims
35.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lenvima Lenvatinib Mesylate | Brand | 51 | $1,207,972 | |
| Pemazyre Pemigatinib | Brand | 23 | $448,632 | |
| Cabometyx Cabozantinib S-Malate | Brand | 21 | $357,329 | |
| Xarelto Rivaroxaban | Brand | 51 | $31,146 | |
| Creon Lipase/Protease/Amylase | Brand | 13 | $26,219 | |
| Enoxaparin Sodium | Generic | 13 | $3,770 | |
| Ursodiol | Generic | 28 | $2,538 | |
| Pantoprazole Sodium | Generic | 50 | $539 | |
| Ondansetron Hcl | Generic | 47 | $446 | |
| Dexamethasone | Generic | 29 | $318 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$72,930
Medicare patients
175
Services billed
803
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 43% | |
| Arthritis | 39% | |
| Ischemic heart disease | 37% | |
| Cancer | 30% | |
| Depression | 24% | |
| Chronic kidney disease | 22% | |
| Atrial fibrillation | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
113 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in New York
Michael Schuster
Hematology & Oncology · New York, NY
Charles Sawyers
Hematology & Oncology · New York, NY
Manuel Hidalgo-Medina
Hematology & Oncology · New York, NY
Francis Arena
Hematology & Oncology · Lake Success, NY
Sanjeev Jain
Hematology & Oncology · East Patchogue, NY
Ross Levine
Hematology & Oncology · New York, NY
Related records
Hematology & Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.